NasdaqGS - Delayed Quote • USD
Seres Therapeutics, Inc. (MCRB)
At close: May 31 at 4:00 PM EDT
After hours: May 31 at 7:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.28 | -0.24 | -1.03 | -0.77 |
| Low Estimate | -0.32 | -0.33 | -1.28 | -1.26 |
| High Estimate | -0.24 | -0.18 | -0.92 | -0.55 |
| Year Ago EPS | 0.36 | -0.37 | -0.89 | -1.03 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 6 | 5 | 6 |
| Avg. Estimate | -- | 80k | -- | 5.25M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | 480k | -- | 31.52M |
| Year Ago Sales | 126.47M | 1.87M | 126.33M | -- |
| Sales Growth (year/est) | -- | -95.70% | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.53 | -0.5 | -0.5 | -0.34 |
| EPS Actual | 0.36 | -0.37 | -0.32 | -0.27 |
| Difference | -0.17 | 0.13 | 0.18 | 0.07 |
| Surprise % | -32.10% | 26.00% | 36.00% | 20.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.28 | -0.24 | -1.03 | -0.77 |
| 7 Days Ago | -0.28 | -0.24 | -1.03 | -0.77 |
| 30 Days Ago | -0.31 | -0.27 | -1.14 | -0.8 |
| 60 Days Ago | -0.31 | -0.27 | -1.14 | -0.8 |
| 90 Days Ago | -0.34 | -0.32 | -1.38 | -0.73 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 4 | 4 | 5 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MCRB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -177.80% | -- | -- | 7.70% |
| Next Qtr. | 35.10% | -- | -- | 10.10% |
| Current Year | -15.70% | -- | -- | 4.60% |
| Next Year | 25.20% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -134.00% | -- | -- | 11.29% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Oppenheimer: Outperform to Outperform | 5/9/2024 |
| Maintains | Chardan Capital: Buy to Buy | 5/8/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/6/2024 |
| Maintains | Chardan Capital: Buy to Buy | 3/6/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/16/2024 |
| Maintains | Goldman Sachs: Sell to Sell | 11/3/2023 |
Related Tickers
AKBA Akebia Therapeutics, Inc.
1.1200
+3.70%
XFOR X4 Pharmaceuticals, Inc.
1.0100
+3.49%
SCPH scPharmaceuticals Inc.
3.9100
-2.49%
PDSB PDS Biotechnology Corporation
2.9800
+1.02%
ADAP Adaptimmune Therapeutics plc
1.1300
+11.88%
MREO Mereo BioPharma Group plc
3.4500
-3.90%
ARDX Ardelyx, Inc.
6.86
+1.18%
IOVA Iovance Biotherapeutics, Inc.
8.88
-1.33%
ALT Altimmune, Inc.
7.51
+6.98%
GLYC GlycoMimetics, Inc.
0.2710
-1.09%